CHOosing Interventions that are Cost Effective (WHO-CHOICE)

AFR D: Cost effectiveness results for Blindness

This Table provides summary results of the total population-level costs, effects and cost-effectiveness for the selected WHO sub-region and risk factor / disease for the year 2000.

KEY
I$ - International Dollars
Program Costs include costs of administration, media, training etc
Patient Costs include costs of hospital visits, drugs, etc
Incremental cost-effectiveness ratio (ICER) is defined as the incremental change in cost, divided by the incremental change in effectiveness. ICERs are reported for the successive set of interventions that would be selected at expanding levels of resource availability, starting with the intervention with the lowest cost per DALY averted, then moving to the next most cost-effective combination intervention out of the remaining available set of interventions.
Dominated is used to denote an intervention that is more costly and/or less effective than other, more efficient (single or combined) interventions; i.e. dominated interventions do not appear on the expansion path of most cost-effective strategies.


Interventions:Codes_and_Descriptions Coverage Cost per year (I$, millions) per one million_population [i.e. cost per capita] % Program costs % Patient costs DALYs averted per year per one million_population Average Cost per DALY averted Incremental Cost per DALY averted
CTR-1: Intra-capsular Cataract extraction using aphakic glasses (50%) 50% 0.61 69% 31% 3,194 190 Dominated
CTR-2: Intra-capsular Cataract extraction using aphakic glasses (80%) 80% 0.83 63% 37% 5,150 161 Dominated
CTR-3: Intra-capsular Cataract extraction using aphakic glasses (95%) 95% 0.97 63% 37% 6,139 158 Dominated
CTR-4: Extra-capsular Cataract extraction with posterior chamber lens implant (50%) 50% 0.63 66% 34% 5,869 107 Dominated
CTR-5: Extra-capsular Cataract extraction with posterior chamber lens implant (80%) 80% 0.87 61% 39% 9,524 91 Dominated
CTR-6: Extra-capsular Cataract extraction with posterior chamber lens implant (95%) 95% 1.02 60% 40% 11,393 89 89
TRC-1: Mass treatment of trachoma with tetracycline ointment (at 50%, 80% and 95% coverage) ALL 1.44 35% 65% 69 20,830 Dominated
TRC-2: Mass treatment of trachoma with azithromycin (at 50%, 80% and 95% coverage) ALL 3.14 14% 86% 349 9,012 Dominated
TRC-3: Targeted treatment of trachoma with azithromycin (at 50%, 80% and 95% coverage) ALL 5.48 8% 92% 246 22,250 Dominated
TRC-4: Targeted treatment of trachoma with surgery (at 80% of current prevalence) 80% 0.12 14% 86% 9,078 13 13
TRC-5: Combination (TRC1 + TRC4) 1.56 32% 68% 9,147 170 Dominated
TRC-6: Combination (TRC2+ TRC4) 3.26 14% 86% 9,427 346 9,012
TRC-7: Combination (TRC3 + TRC4) 5.60 8% 92% 9,325 600 Dominated
Share